We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$390M
AUM Growth
+$73M
Cap. Flow
+$37.6M
Cap. Flow %
9.65%
Top 10 Hldgs %
76.67%
Holding
31
New
3
Increased
11
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
LBRDK icon
Liberty Broadband Class C
LBRDK
+$113M
2
ARGX icon
argenx
ARGX
+$19.4M
3
EYPT icon
EyePoint Inc
EYPT
+$16.3M
4
TVTX icon
Travere Therapeutics
TVTX
+$1.8M
5
RVMD icon
Revolution Medicines
RVMD
+$1.78M

Top Sells

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$29M
2
FOLD
Amicus Therapeutics
FOLD
+$21.1M
3
HPLTW
Home Plate Acquisition Corporation Warrant
HPLTW
+$20M
4
CYTK icon
Cytokinetics
CYTK
+$15M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.75%
2 Communication Services 27.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBRDK icon
1
Liberty Broadband Class C
LBRDK
$4.43B
$108M 27.68%
1,886,260
+1,701,800
+923% +$113M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$29.2M 7.48%
592,528
+35,600
+6% +$1.65M
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$26.6M 6.81%
175,672
+11,900
+7% +$1.7M
ARVN icon
4
Arvinas
ARVN
$517M
$22.3M 5.71%
539,100
+34,400
+7% +$1.5M
RVMD icon
5
Revolution Medicines
RVMD
$39.6B
$21.8M 5.6%
677,100
+60,000
+10% +$1.78M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.82B
$20.5M 5.26%
158,457
+13,100
+9% +$1.6M
ARGX icon
7
argenx
ARGX
$53.8B
$19.7M 5.05%
+50,000
New +$19.4M
MLTX icon
8
MoonLake Immunotherapeutics
MLTX
$1.64B
$18.1M 4.65%
360,916
-534,084
-60% -$29M
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$16.7M 4.28%
238,046
-193,647
-45% -$15M
LKFT
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$16.2M 4.16%
503,759
+45,100
+10% +$1.68M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.38B
$15.5M 3.99%
840,453
+70,800
+9% +$1.75M
EYPT icon
12
EyePoint Inc
EYPT
$1.12B
$13.6M 3.48%
+656,600
New +$16.3M
SLDB icon
13
Solid Biosciences
SLDB
$858M
$12.8M 3.28%
961,251
– –
TVTX icon
14
Travere Therapeutics
TVTX
$5.27B
$12.7M 3.26%
1,649,221
+213,900
+15% +$1.8M
RLAY icon
15
Relay Therapeutics
RLAY
$4.34B
$12.4M 3.17%
1,490,170
+172,300
+13% +$1.68M
PRTA icon
16
Prothena Corp
PRTA
$453M
$9.97M 2.56%
402,400
+53,100
+15% +$1.58M
CVIIW
17
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$175K 0.05%
548,000
– –
MNYWW
18
MoneyHero Ltd Warrants
MNYWW
$108K 0.03%
+895,000
New +$63.5K
CLDI icon
19
Calidi Biotherapeutics
CLDI
$2.3M
$70.6K 0.02%
1,042
– –
CNDA.WS
20
DELISTED
Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
CNDA.WS
$45.4K 0.01%
408,333
– –
CDAQW
21
DELISTED
Compass Digital Acquisition Corp. Warrant
CDAQW
$42.3K 0.01%
459,906
– –
CLDI.WS
22
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
$34.1K 0.01%
655,200
– –
IVCPW
23
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$27.4K 0.01%
490,000
– –
LSBPW
24
DELISTED
LakeShore Biopharma Warrants
LSBPW
$25K 0.01%
489,999
– –
GATEW
25
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$8.23K ﹤0.01%
735,000
– –
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Finepoint Capital held 31 positions worth $390M, up 23% from $317M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Finepoint Capital deployed $37.6M of net new capital in Q1 2024, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was argenx: 50,000 shares worth $19.7M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 80% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was MoonLake Immunotherapeutics, an estimated $29M trimmed.

  • Finepoint Capital's largest Q1 2024 buy was argenx: 50,000 shares worth $19.7M.
  • Finepoint Capital added most to Liberty Broadband Class C in Q1 2024, an estimated $113M increase.
  • Finepoint Capital's biggest Q1 2024 reduction was MoonLake Immunotherapeutics, cutting an estimated $29M.
  • Finepoint Capital fully exited Amicus Therapeutics in Q1 2024, selling an estimated $21.1M.
  • Finepoint Capital's ten largest holdings make up 77% of its $390M portfolio in Q1 2024.
  • Finepoint Capital opened 3 new positions and closed 5 in Q1 2024.
  • Finepoint Capital's portfolio value rose 23% quarter-over-quarter to $390M.

Based on Finepoint Capital's 13F filing for Q1 2024, filed 14 May 2024.